Below is a press release from Charles River Laboratories, which is headquartered in Wilmington:
WILMINGTON, MA — Charles River Laboratories International recently announced a strategic partnership with Kibur Medical to offer exclusive access to its implantable microdevice (IMD) for in vivo preclinical oncology studies.
Kibur’s Unique Technology
The IMD provides an opportunity to transform how researchers may assess efficacy of oncology compounds in vivo as both individual and combination therapies. Kibur’s microdevice technology can hold up to 20 different compounds for local administration.
According to a study in Biostatistics, oncology drugs have a 97% failure rate in clinical trials. Together with Charles River’s leading expertise in early-stage preclinical testing, researchers can utilize the Kibur technology to perform in vivo testing of multiple doses and multiple combinations of oncology or immune-oncology therapies in small cohorts of patient-derived xenograft (PDX), cell-line derived or syngeneic models. Additionally, Kibur’s IMD provides both a platform to observe synergies of drug combinations and a time and cost-sensitive testing solution for extending indications of existing oncology drugs.
Excised tumor tissue is analyzed via multiplex immuno-histochemistry, immune cell readouts, spatial transcriptomics and MALDI-TOF mass spectrometry providing for rich datasets in short cycle times and thereby improved decision making early in the preclinical process.
About Kibur Medical
Kibur Medical is a clinical stage biomedical company that develops devices and microsensors for in vivo applications. The company focuses on applications of its technology to develop precision treatments for cancer and other diseases, as well as enabling more efficient drug development in the preclinical and clinical space.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
Like Wilmington Apple on Facebook. Follow Wilmington Apple on Twitter. Follow Wilmington Apple on Instagram. Subscribe to Wilmington Apple’s daily email newsletter HERE. Got a comment, question, photo, press release, or news tip? Email email@example.com.